BioCentury
ARTICLE | Clinical News

Seek reports Phase Ib/II data for HIV vaccine

July 19, 2011 12:22 AM UTC

Seek Ltd. (London, U.K.) said a single subcutaneous injection of its high-dose HIV-v vaccine with adjuvant reduced HIV viral load by about 90% from baseline to six months vs. placebo in a Phase Ib/II ...